11th LIPIDCLUB 2016 The MIGHTY MEDIC Gobal Scientific Society
[slideshow_deploy id=’1008′]
WAA/SFH Joint Congress, Paris, 27–29 April 2016
WAA/SFH Joint Congress, Paris, 27–29 April 2016
Author Archives: Mighty Medic
11th LIPIDCLUB 2016 The MIGHTY MEDIC Gobal Scientific Society
World Congress on Clinical Lipidology 10 – 12 February, 2017 Brisbane, Australia
World Congress on Clinical Lipidology 10 – 12 February, 2017 Brisbane, Australia
EFFICACY OF ALIROCUMAB IN 1,191 PATIENTS WITH A WIDE SPECTRUM OF MUTATIONS IN GENES CAUSATIVE FOR FAMILIAL HYPERCHOLESTEROLEMIA
Authors: John J.P. Kastelein, Gisle Langslet, Paul Hopkins, Joep Defesche, Werner Seiz, Marie Baccara-Dinet, Sara Hamon, Poulabi Banerjee, Claudia Stefanutti, Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA, Sanofi, Montpellier, France Background: Next Generation Sequencing was performed to examine treatment response with alirocumab in patients carrying one or more causative mutation(s) in five familial …
Efficacy of Alirocumab in 1191 Patients with a Wide Spectrum of Mutations in Genes Causative for Familial Hypercholesterolemia
Familial hypercholesterolemia (FH) is characterized by high levels of low-density lipoprotein cholesterol (LDL-C) and increased risk of developing premature coronary heart disease. The prevalence of heterozygous and homozygous FH has been estimated to be 1:200 to 1:500 and 1:160,000 to 1:1,000,000, respectively. In plasma, LDL-C levels are regulated via apolipoprotein …
The third annual congress of the Association for Preventive Pediatrics Serbia with international participation
“PREVENTION IN PEDIATRICS – BASIS FOR HEALTHY LIFE AND LONGEVITY” 15 – 17 April 2016. Hotel Holiday Inn, Belgrade
Serbia Assoc of Peds
Serbia Assoc of Peds: Final Program [slideshow_deploy id=’1019′]
Immunoadsorption apheresis and immunosuppressive drug therapy in the treatment of complicated HCV-related cryoglobulinemia.
http://www.ncbi.nlm.nih.gov/pubmed/19927363
Therapeutic plasma exchange in patients with severe hypertriglyceridemia: a multicenter study.
http://www.ncbi.nlm.nih.gov/pubmed/20091936
Relationship between Sustained Reductions in Plasma Lipid and Lipoprotein Concentrations with Apheresis and Plasma Levels and mRNA Expression of PTX3 and Plasma Levels of hsCRP in Patients with HyperLp(a)lipoproteinemia.
The effect of lipoprotein apheresis (Direct Adsorption of Lipids, DALI) (LA) on plasma levels of pentraxin 3 (PTX3), an inflammatory marker that reflects coronary plaque vulnerability, and expression of PTX3 mRNA was evaluated in patients with hyperLp(a)lipoproteinemia and angiographically defined atherosclerosis/coronary artery disease. Eleven patients, aged 55 ± 9.3 years …